Tele: 561.316.3330

Breaking Medical Device Industry News

Tuesday, October 26, 2021

MEDICAL DEVICE NEWS MAGAZINE

A DIGITAL PUBLICATION FOR THE PRACTICING MEDICAL SPECIALIST, INDUSTRY EXECUTIVE AND INVESTOR
HomeGamma MedicaHenry Ford Cancer Institute Announce the Availability of LumaGEM® Molecular Breast Imaging...

Henry Ford Cancer Institute Announce the Availability of LumaGEM® Molecular Breast Imaging (MBI) Machine


The new technology was made possible by philanthropic support and donations

Gamma Medica, molecular breast imaging (MBI) technology, announced today that the Henry Ford Cancer Institute has installed Gamma Medica’s LumaGEM® Molecular Breast Imaging system, which is the first MBI machine in Michigan. MBI is a proven, effective supplementary screening method to standard mammography and/or tomosynthesis (3D mammography), significantly increasing early detection of breast cancer in women.1 The new system can be found at the Henry Ford West Bloomfield Hospital where it will provide diagnostic and secondary screenings to women who have a higher risk of breast cancer and with dense breast tissue.

Approximately 50 percent of U.S. women are reported to have dense breast tissue. Unfortunately, many do not realize that they have dense tissue, or the implications dense breast tissue has on increasing their lifetime risk of breast cancer.2 Additionally, both dense breast tissue and cancer appear white on mammograms, making it difficult to distinguish between the two. It’s like trying to find a snowflake in a snowstorm, which can lead to false negatives or delayed diagnoses.3

“The new installation of the LumaGEM MBI system at the Henry Ford Cancer Institute gives women in Michigan and surrounding areas access to a clinically superior diagnostic and secondary breast screening method,” said Philip Croxford, president and CEO of Gamma Medica. “We are delighted to be able to partner with the Henry Ford Cancer Institute and look forward to collaborating with them to help improve early cancer detection for women who are at greater risk. We believe MBI will ensure that more women have the opportunity to receive personalized breast screenings and improved clinical outcomes.”

A prospective study conducted by the Mayo Clinic in Rochester, MN found that the addition of MBI to mammography significantly increased the detection of breast cancer in women with dense breast tissue.4 The following year, a retrospective clinical study published in the American Journal of Roentgenology’s August 2016 issue confirmed these findings. This study involved nearly 1,700 women with dense breast tissue over a three year period and found that LumaGEM had an incremental cancer detection rate of 7.7 cancers per thousand (7.7/1000) over mammography (which detects 3.0/1000 alone). Approximately 85 percent of the cancers found in the study were confirmed to be invasive, of which 82 percent were node negative, indicating they were detected at an early stage and therefore presented a better prognosis.5 Clinical research also showcases that the use of LumaGEM reduces biopsies, often painful and costly, by 50 percent, compared to other modalities.6 The MBI procedure requires minimal breast compression; patients are able to sit comfortably throughout the exam and results are typically available the same day.

“The Henry Ford Cancer Institute offers some of the most advanced screening options available to our patients, and this technology brings added imaging capability for women with dense breast tissue,” says Patricia Miller, M.D., director of Breast Imaging at Henry Ford West Bloomfield Hospital.

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Stay Connected

spot_img

Don't Miss

By using this website you agree to accept Medical Device News Magazine Privacy Policy